← All trials
NCT05522868
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 17, 2022
- Primary completion
- Jan 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Aug 31, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 50
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Spark TherapeuticsLead sponsor
- Spark TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.